Literature DB >> 35065946

Prediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.

Prashanthi N Thota1, Jalil Nasibli2, Prabhat Kumar1, Madhusudhan R Sanaka1, Amitabh Chak3, Xuefeng Zhang4, Xiuli Liu5, Shikhar Uttam6, Yang Liu2.   

Abstract

BACKGROUND AND AIMS: Nanoscale nuclear architecture mapping (nanoNAM), an optical coherence tomography-derived approach, is capable of detecting with nanoscale sensitivity structural alterations in the chromatin of epithelial cell nuclei at risk for malignant transformation. Because these alterations predate the development of dysplasia, we aimed to use nanoNAM to identify patients with Barrett's esophagus (BE) who might progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).
METHODS: This is a nested case-control study of 46 BE patients, of which 21 progressed to HGD/EAC over 3.7 ± 2.37 years (cases/progressors) and 25 patients who did not progress over 6.3 ± 3.1 years (control subjects/nonprogressors). The archived formalin-fixed paraffin-embedded tissue blocks collected as part of standard clinical care at the index endoscopy were used. nanoNAM imaging was performed on a 5-μm formalin-fixed paraffin-embedded section, and each nucleus was mapped to a 3-dimensional (3D) depth-resolved optical path difference (drOPD) nuclear representation, quantifying nanoscale-sensitive alterations in the 3D nuclear architecture of the cell. Using 3D-drOPD representation of each nucleus, we computed 12 patient-level nanoNAM features summarizing the alterations in intrinsic nuclear architecture. A risk prediction model was built incorporating nanoNAM features and clinical features.
RESULTS: A statistically significant differential shift was observed in the drOPD cumulative distributions between progressors and nonprogressors. Of the 12 nanoNAM features, 6 (mean-maximum, mean-mean, mean-median, entropy-median, entropy-entropy, entropy-skewness) showed a statistically significant difference between cases and control subjects. NanoNAM features based prediction model identified progression in independent validation sets, with an area under the receiver operating characteristic curve of 80.8% ± .35% (mean ± standard error), with an increase to 82.54% ± .46% when combined with length of the BE segment.
CONCLUSIONS: NanoNAM can serve as an adjunct to histopathologic evaluation of BE patients and aid in risk stratification.
Copyright © 2022 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35065946      PMCID: PMC9296222          DOI: 10.1016/j.gie.2022.01.007

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   10.396


  22 in total

Review 1.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

Review 2.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

3.  Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus.

Authors:  Prashanth Vennalaganti; Vijay Kanakadandi; John R Goldblum; Sharad C Mathur; Deepa T Patil; G Johan Offerhaus; Sybren L Meijer; Michael Vieth; Robert D Odze; Saligram Shreyas; Sravanthi Parasa; Neil Gupta; Alessandro Repici; Ajay Bansal; Titi Mohammad; Prateek Sharma
Journal:  Gastroenterology       Date:  2016-11-03       Impact factor: 22.682

4.  A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.

Authors:  L C Duits; P Lao-Sirieix; W A Wolf; M O'Donovan; N Galeano-Dalmau; S L Meijer; G J A Offerhaus; J Redman; J Crawte; S Zeki; R E Pouw; A Chak; N J Shaheen; J J G H M Bergman; R C Fitzgerald
Journal:  Dis Esophagus       Date:  2019-01-01       Impact factor: 3.429

5.  Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.

Authors:  Sravanthi Parasa; Sreekar Vennalaganti; Srinivas Gaddam; Prashanth Vennalaganti; Patrick Young; Neil Gupta; Prashanthi Thota; Brooks Cash; Sharad Mathur; Richard Sampliner; Fouad Moawad; David Lieberman; Ajay Bansal; Kevin F Kennedy; John Vargo; Gary Falk; Manon Spaander; Marco Bruno; Prateek Sharma
Journal:  Gastroenterology       Date:  2017-12-19       Impact factor: 22.682

6.  Chronology of the Barrett's metaplasia-dysplasia-carcinoma sequence.

Authors:  J Theisen; J J Nigro; T R DeMeester; J H Peters; O L Gastal; J A Hagen; M Hashemi; C G Bremner
Journal:  Dis Esophagus       Date:  2004       Impact factor: 3.429

7.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

8.  Fourier phase in Fourier-domain optical coherence tomography.

Authors:  Shikhar Uttam; Yang Liu
Journal:  J Opt Soc Am A Opt Image Sci Vis       Date:  2015-12-01       Impact factor: 2.129

9.  Genomic copy number predicts esophageal cancer years before transformation.

Authors:  Sarah Killcoyne; Eleanor Gregson; David C Wedge; Dan J Woodcock; Matthew D Eldridge; Rachel de la Rue; Ahmad Miremadi; Sujath Abbas; Adrienn Blasko; Cassandra Kosmidou; Wladyslaw Januszewicz; Aikaterini Varanou Jenkins; Moritz Gerstung; Rebecca C Fitzgerald
Journal:  Nat Med       Date:  2020-09-07       Impact factor: 53.440

10.  Clinical prediction model for tumor progression in Barrett's esophagus.

Authors:  Dag Holmberg; Eivind Ness-Jensen; Fredrik Mattsson; Jesper Lagergren
Journal:  Surg Endosc       Date:  2018-11-19       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.